Bhaumik 2002.

Methods	Study design: parallel group RCT Time frame: January 1996 to March 2000 Follow up period: 6 months
Participants	Setting: Tertiary centre Country: India SRNS (biopsy proven primary FSGS); no response to 8 weeks of prednisolone (2 mg/kg/d) Number (group A/group B): 13/12 Age range: 3 to 49 years Sex (M/F): not reported but stated similar between groups Exclusion criteria: SSNS
Interventions	Group A Cyclosporin 1 to 4 mg/kg/day with oral prednisolone for at least 6 months Group B Methylprednisolone 250‐750 mg IV daily for 7 days and then weekly for at least 12 weeks Co‐interventions BP control Dietary protein 0.8 to 1.0 g/kg/d ACE inhibitors Lipid lowering agents
Outcomes	Complete remission Decline in proteinuria & stable creatinine Progression to ESKD Rate of decline in GFR Hospitalisation for therapy related complications
Notes	Abstract‐only publication Funding source not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Study described as randomised; method of randomisation not reported
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No information provided on how outcome was measured
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for
Selective reporting (reporting bias)	Unclear risk	Abstract‐only publication
Other bias	Unclear risk	Insufficient information to permit judgement